Savara Inc. Aktie
3,80 €
Deine Einschätzung
Savara Inc. Aktie
Was spricht für und gegen Savara Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Savara Inc. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Savara Inc. | -0,52 % | 1,06 % | -11,21 % | 49,61 % | -12,04 % | 160,27 % | -60,76 % |
Rockwell Medical Inc. | 1,12 % | -1,33 % | 19,69 % | -33,65 % | -6,06 % | -78,60 % | -96,31 % |
Avid Bioservices Inc | -0,68 % | -9,88 % | 2,10 % | -48,95 % | 19,67 % | -58,05 % | 113,17 % |
Gritstone Oncology Inc | -1,05 % | -7,23 % | -8,47 % | -57,73 % | -63,05 % | -90,89 % | - |
Kommentare
News
Savara to Present at the Jefferies Global Healthcare Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
On May 14, 2024